This article is more than 5 years old. Information may no longer be current.

FDA approves Paragon's phenylephrine solution

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Paragon Biotek Inc. announced U.S. Food and Drug Administration approval of its phenylephrine HCl ophthalmic solution, 2.5% and 10%, for pupil dilation.

The solution is immediately available through Bausch + Lomb, Paragon said in a press release.

"Paragon is committed to working proactively with the FDA in an effor to prevent disrupting supply of this and future drugs that play a vital role in managing ocular health," Patrick H. Whitham, Paragon president and CEO, said in the release.